Jyong Biotech (NASDAQ:MENS) Stock Price Down 4.3% – Time to Sell?

Jyong Biotech Ltd. (NASDAQ:MENS)’s stock price was down 4.3% during trading on Thursday . The company traded as low as $27.98 and last traded at $27.98. Approximately 25,047 shares were traded during trading, a decline of 91% from the average daily volume of 278,352 shares. The stock had previously closed at $29.25.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Jyong Biotech in a report on Wednesday, October 8th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company presently has an average rating of “Sell”.

Jyong Biotech Price Performance

The stock’s fifty day moving average price is $44.62.

Institutional Trading of Jyong Biotech

An institutional investor recently bought a new position in Jyong Biotech stock. BNP Paribas Financial Markets purchased a new position in shares of Jyong Biotech Ltd. (NASDAQ:MENS) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 1,698 shares of the company’s stock, valued at approximately $67,000.

About Jyong Biotech

OUR MISSION We endeavor to develop and supply first-class innovative drugs to meet our customers’ health needs. We seek to be a valuable business organization that is held in high esteem by the public. We are a science-driven biotechnology company based in Taiwan and are committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU, and Asia.